NasdaqHealth CarePharmaceutical PreparationsMIAMI BEACH, FL

Pasithea Therapeutics Corp. KTTA

Ask your AI

Estimated market cap $19.18M36.75M shares, shares as of Nov 12, 2026CIK 1841330

Insider trades, 12 mo

4 buys · 0 sells

$203.0K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

14.6% of shares · 4 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Pasithea Therapeutics Corp.'s latest quarterly report, compared with the one before.

Filed Nov 13, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Pasithea Therapeutics Corp.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

4 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 17, 2026. Insiders have two business days to file.

Recent insider trades

Coastlands Capital LP 10% owner	Jun 17 Form 4 ↗	Buy	+$53.0K 100,000 sh @ $0.53	+2.1%
Lawrence Steinman Director	Nov 28, 2025 Form 4 ↗	Buy	+$100.0K 133,333 sh @ $0.75	-74.9%
Tiago Marques Chief Executive Officer, Director	Nov 28, 2025 Form 4 ↗	Buy	+$25.0K 33,333 sh @ $0.75	-74.9%
Simon Dumesnil Director	Nov 28, 2025 Form 4 ↗	Buy	+$25.0K 33,333 sh @ $0.75	-74.9%
Tiago Marques Chief Executive Officer, Director	May 12, 2025 Form 4 ↗	Sale	−$797 960 sh @ $0.83	-69.4%

All KTTA insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

5.36M shares

14 funds report KTTA. Values checked against market prices.

Funds own 50% of shares (Q2 2026)

25 funds hold the stock.

Q3 2026: 15% · 5,560 of ~8,900 funds reported so far

Q1 20252.9%
Q2 20254.0%
Q3 20258.2%
Q1 202651%
Q2 202650%
Q3 2026 (so far)15%

Q3 2026. 3 new, 4 added to, 2 trimmed, 15 exited since Q2 2026.

Top 13F holders
#
1	Stonepine Capital Management, LLC 13F ↗	2.77M	$1.4M	+26.0%
2	AdvisorShares Investments LLC 13F ↗	1.16M	$571.9K	+23.7%
3	Vivo Capital, LLC 13F ↗	372,796	$183.8K	-19.9%
4	Persistent Asset Partners Ltd 13F ↗	290,555	$143.2K	unchanged
5	Geode Capital Management, LLC 13F ↗	177,996	$87.8K	+112.3%
6	Vanguard Fiduciary Trust Co 13F ↗	172,328	$85.0K	+292.9%
7	Jane Street Group, LLC 13F ↗	143,062	$70.5K	New
8	Vanguard Capital Management LLC 13F ↗	126,279	$62.3K	unchanged
9	HRT Financial LP 13F ↗	99,683	$49.0K	n/a
10	State Street Corp 13F ↗	40,800	$20.1K	New

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds KTTA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Pasithea Therapeutics Corp. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Pasithea Therapeutics Corp. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2024	6	—	30,205	$219.2K
Q2 2024	7	+1	30,146	$152.4K
Q3 2024	6	-1	9,236	$49.7K
Q4 2024	7	+1	77,162	$243.3K
Q1 2025	8	+1	78,954	$99.1K
Q2 2025	11	+3	300,844	$216.6K
Q3 2025	19	+8	612,404	$441.5K
Q4 2025	25	+6	12.89M	$16.6M
Q1 2026	21	-4	12.82M	$9.5M
Q2 2026	25	+4	16.79M	$8.7M
Q3 2026	14	-11	5.36M	$2.6M

Each point is a quarter-end, from Q1 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (70261F202). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes16 in 12 mo 8-K events3 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history4 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Pasithea Therapeutics Corp.
Address: 1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL 33139
Phone: (702) 514-4174
Fiscal year ends: Dec 31
Filer category: emerging growth company
Incorporated in: DE
Listed as: KTTA (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.522+$0.00 (+0.40%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.368 · High $0.5788Nov 13, 2026

Aug 13, 2026Low $0.368 · High $0.599Nov 13, 2026

Nov 13, 2025Low $0.2923 · High $1.47Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.